What Does the Evidence Say About Ozempic and Gastroparesis?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Exposure Awareness

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be concerned about gastroparesis—a condition where stomach emptying slows. Decades of pharmacovigilance research have established that GLP-1 receptor agonists can affect gastrointestinal motility, raising important questions about long-term safety. This page reviews the current evidence on Ozempic and gastroparesis, including clinical findings and follow-up considerations for North Carolina patients.

Bridging Legacy Frameworks and Emerging Pharmaceutical Risks

Building on the need to update legacy health frameworks, it is essential to examine the specific risks associated with Ozempic (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Among its known adverse effects, gastrointestinal (GI) reactions are prominent. In placebo-controlled trials, GI adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to GI adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, GI adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional GI adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in GI side effects, which may be relevant to the development of gastroparesis.

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction. Clinical presentation includes early satiety, postprandial fullness, nausea, vomiting, and abdominal pain. Diagnosis is typically confirmed by gastric emptying scintigraphy. The mechanistic pathways linking Ozempic to gastroparesis involve GLP-1 receptor activation, which slows gastric motility and can exacerbate or unmask underlying gastroparesis. While the prescribing information does not explicitly list gastroparesis as an adverse reaction, the high rates of nausea, vomiting, dyspepsia, and gastroesophageal reflux disease suggest a potential for delayed gastric emptying. The adequacy of warnings regarding Ozempic and gastroparesis is a key risk consideration. The label includes warnings for serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but does not specifically warn about gastroparesis. This gap may affect patient awareness and informed consent.

Statute of Limitations for Ozempic Claims in North Carolina

For affected patients in North Carolina, settlement-related considerations depend on the statute of limitations for product liability claims. In North Carolina, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For claims involving harm from a prescription drug, the timeline between exposure to Ozempic and documented harm is critical. Patients who developed gastroparesis symptoms during or after Ozempic use should document the onset of symptoms, the date of diagnosis, and any correlation with dose escalation. The evidence shows that GI adverse reactions often occur during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), which may help establish a temporal link. Settlement considerations also involve the strength of the causal link. While the label reports GI reactions, it does not quantify the risk of gastroparesis specifically. Patients may need to rely on expert testimony to establish that Ozempic can cause or contribute to gastroparesis. The high discontinuation rates due to GI adverse reactions (3.1% for 0.5 mg and 3.8% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166) indicate that these effects are clinically significant. However, the absence of a specific warning may be a factor in litigation.

Legal and Medical Considerations for Affected Individuals

In summary, patients in North Carolina who have developed gastroparesis after using Ozempic should be aware of the statute of limitations, which is typically three years from discovery of harm. They should gather medical records documenting the timeline of Ozempic use, symptom onset, and diagnosis. The evidence from clinical trials shows a clear increase in GI adverse reactions with Ozempic, but the label does not specifically address gastroparesis. This may be relevant to claims of inadequate warnings. Legal consultation is recommended to assess individual circumstances and the applicability of settlement options. References - https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in North Carolina?

In North Carolina, the statute of limitations for personal injury claims, including those related to prescription drugs, is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For Ozempic-related gastroparesis, this means you typically have three years from the date you discovered or should have discovered that your gastroparesis was linked to Ozempic use.

Does the Ozempic label warn about gastroparesis?

The Ozempic prescribing information does not explicitly list gastroparesis as an adverse reaction. However, it does report high rates of gastrointestinal side effects such as nausea, vomiting, dyspepsia, and gastroesophageal reflux disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The absence of a specific warning about gastroparesis may be relevant to claims of inadequate warnings.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.